Science Board to the Food and Drug Administration via Videoconference June 14, 2022

AGENDA

9:00 a.m. Opening Introductions

Barbara Kowalcyk, PhD, Science Board Chair

9:05 a.m. Conflict of Interest

Rakesh Raghuwanshi, MPH, Designated Federal Officer, Science Board, FDA

9:10 a.m. New Alternative Methods

Janet Woodcock, MD, Principal Deputy Commissioner, FDA

David Strauss, MD, PhD, Director, Division of Applied Regulatory Science, CDER

Jacqueline O'Shaughnessy, PhD, Acting Chief Scientist, FDA

10:10 a.m. Commissioner's Update and Data Science Efforts

Robert Califf, MD, Commissioner of Food and Drugs, FDA

11:00 a.m. Open Public Hearing

12:00 p.m. Break

12:30 p.m. CFSAN Session: Challenges in evaluating the safety of dietary supplement and food ingredients with predicted pharmacological activity

Janet Woodcock, MD, Principal Deputy Commissioner, FDA

Patrick Cournoyer, PhD, Acting Science and Policy Coordinator, Cannabis Product Committee, Office of the Commissioner

Cassandra Taylor, PhD, Chemist, Botanical Review Team, Office of Pharmaceutical Quality, CDER, FDA

Gregory Noonan, PhD, Acting Deputy Director, Office of Dietary Supplement Programs, CFSAN, FDA

Jeremy Gingrich, PhD, Toxicologist, Office of Food Additive Safety, CFSAN, FDA

Steven Musser, PhD, Deputy Director for Scientific Operations, CFSAN, FDA

4:30 p.m. Final Thoughts, and Closing Comments

Barbara Kowalcyk, PhD, Science Board Chair